Irritable bowel syndrome (IBS) is a disorder of brain–gut interaction characterized by recurrent abdominal pain and altered bowel habits. While prior work suggests that music-based interventions (MBIs) can reduce pain and stress in some populations, the mechanisms by which MBIs might affect IBS pain are not well characterized. This protocol specifies a single-arm pilot mechanistic trial to examine both clinical responses and multimodal mechanistic signals associated with an MBI in adults with IBS. A concurrent objective is to evaluate the feasibility of extending physiological monitoring from laboratory into home settings using wearable biosensing devices.
This is a single-arm mechanistic pilot trial enrolling 36 adults aged 18–50 years with provider-confirmed IBS. The authors expect approximately 30 participants to complete the post-intervention laboratory visit. All participants will provide electronic informed consent prior to undergoing any study procedures. The protocol was approved by the Yale University Institutional Review Board (IRB #2000039033) and the trial is registered on ClinicalTrials.gov (NCT06706778).
The intervention consists of a standardized 20-minute MBI protocol. Participants will take part in board-certified music therapist–guided laboratory sessions and then complete four weeks of self-administered home practice. Home practice is prescribed at least five days per week. The protocol emphasizes a standardized approach to ensure consistency across guided and self-administered exposures.
Guided by a brain–gut mechanistic framework, the protocol includes multiple assessment domains:
Patient-reported outcomes: measures of pain intensity, perceived stress, and IBS symptom severity collected longitudinally.
Quantitative sensory testing: laboratory-based sensory assessments to characterize pain sensitivity and related responses.
Gut microbiome profiling: stool samples will undergo 16S rRNA gene sequencing to describe microbial community structure and exploratory associations with clinical and physiological responses.
Multimodal physiological recordings: neural, autonomic, and muscular activity will be recorded to capture mechanistic signals associated with MBI exposure. The protocol aims to characterize both within-session changes (acute responses during guided sessions) and longitudinal changes across the four-week home practice period.
These assessments are intended to identify candidate mechanisms that could mediate MBI effects on IBS pain and inform outcome selection for a future randomized controlled trial.
A core aim is to assess the feasibility of using wearable biosensing devices outside the laboratory. The study will collect multimodal physiological recordings in both lab and home settings to evaluate data completeness and the practicality of remote monitoring. Feasibility metrics explicitly include recruitment and retention rates, adherence to the MBI home practice schedule, completeness and quality of wearable device data, and participant acceptability of the intervention and monitoring procedures.
The protocol notes that wearable biosensing devices were developed and provided by Zemi Labs Inc., which also contributed to the technical implementation of the study application used for data capture.
Analyses will characterize within-session (acute) and longitudinal changes in clinical measures and mechanistic signals. The protocol specifies evaluation of recruitment, retention, adherence, wearable data completeness, and acceptability to determine feasibility parameters. Outcomes from these pilot analyses will guide selection of candidate mechanisms and wearable monitoring strategies to be tested in a subsequent adequately powered randomized controlled trial. The protocol manuscript does not report study results; data will be generated and analyzed under the approved protocol once the trial is conducted.
The study protocol received institutional review board approval from Yale University (IRB #2000039033). All participants will provide electronic informed consent. The trial registration identifier is ClinicalTrials.gov NCT06706778. The authors declare that J.M.T. and K.J.M. are affiliated with Zemi Labs Inc.; Zemi Labs provided the wearable devices and technical implementation but, according to the authors, had no role in participant recruitment, statistical analysis, interpretation of findings, or the decision to submit the manuscript. The remaining authors declared no conflicts of interest.
Funding sources declared include the National Center for Complementary and Integrative Health and the National Endowment for the Arts via specified awards and subawards. The protocol manuscript states that no datasets were generated or analyzed for its preparation. Data produced during the course of the trial will be managed and shared in accordance with the approved study protocol, institutional policies, and applicable data-sharing regulations.